Hologic Inc. closed 22.70% short of its 52-week high of $84.67, which the company reached on August 9th.

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As of ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

RBC Capital analyst Conor McNamara lowered the firm’s price target on Hologic (HOLX) to $85 from $88 and keeps a Sector Perform rating on the ...

Madison Keys, who captured her first Grand Slam title last month in Melbourne, has not played since her title-run Down Under.

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

The company guided Q2 2025 revenues to be between $995 million and $1.005 billion, with non-GAAP EPS expected in the range of $1 to $1.03. Full-year revenue guidance was revised to $4.05 billion to $4 ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Hologic (HOLX – Research Report) yesterday. The company’s shares closed yesterday at ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

Explore advancements in women's health through AI, equity, and policy with Mia Keeys of Hologic on I Don’t Care.

The stock's rise snapped a three-day losing streak.